课题基金 / 基金详情

项目摘要

项目成果

KEVIN J. CULLEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions): The Translational Laboratory Shared Service (TLSS) supports investigators performing drug development in the preclinical and clinical settings at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC). Sen/ices include processing of human clinical trial specimens, developing assays for pharmacodynamic endpoints, assaying novel cancer therapeutics in vitro, and evaluating novel agents aloneor in combination in in vivo cancer models. The TLSS supports both the clinician and basic investigator. For the clinician, the TLSS processes tissue generated from clinical trials, often playing the role of conduit between the clinical trialist and other cores and shared services within UMGCC. Standard operating procedures for processing the material are generated within TLSS and distributed to the necessary personnel involved in administering the clinical trial. In addition, TLSS develops assays to test the functional activity of a novel compound in human tissue from Phase I and Phase l/ll clinical trials. Last, for those clinicians without laboratories of their own, the TLSS provides the opportunity for the clinician to perform basic research or to train residents or interns in laboratory research. A preclinical investigator may choose to utilize TLSS services when the scope of an experiment exceeds the resources available or is outside his or her area of expertise. For example, regarding In vivo work, investigators may prefer to use the TLSS's umbrella animal use protocol (AUP) rather than writing an AUP of their own and processing it through the Institutional Animal Care and Use Committee. Also, TLSS is uniquely set up to screen compounds in multiple cell lines to determine the range, extent, or specificity of efficacy. TLSS personnel meet with both clinicians and basic researchers to discuss experimental designs as well as expected outcomes and appropriate controls. The TLSS is an excellent resource for researchers to use at UMGCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting PI3Kalpha beta and the ErbB family of protein-tyrosine kinases in cisplatin-resistant head and neck squamous cell carcinomas (HNSCC)
  • 批准号:
    10667253
  • 项目类别:
  • 资助金额:
    $37.63万
  • 财政年份:
    2022
  • 负责人:
    KEVIN J. CULLEN
  • 依托单位:
Program Leaders of Research Programs
  • 批准号:
    8711295
  • 项目类别:
  • 资助金额:
    $8.21万
  • 财政年份:
    2014
  • 负责人:
    KEVIN J. CULLEN
  • 依托单位:
Cancer Center Administration
  • 批准号:
    8711298
  • 项目类别:
  • 资助金额:
    $9.74万
  • 财政年份:
    2014
  • 负责人:
    KEVIN J. CULLEN
  • 依托单位:
Program Leaders
  • 批准号:
    8340231
  • 项目类别:
  • 资助金额:
    $8.47万
  • 财政年份:
    2011
  • 负责人:
    KEVIN J. CULLEN
  • 依托单位:
海外基金